Citations

Clear

9383 citation(s) found for "Thomas, PS".

Acute Hyponatremia as a Telling Complication of Necrotizing Pancreatitis and Perforated Cholecystitis After Percutaneous Cholecystostomy
Lee, J T, Kubey, Alan, Kubey, Alan A

Mayo Clinic

ACG Case Reports Journal | June 19, 2026 | Volume: 13 | Issue: 6 | Pages: No page available

10.14309/crj.0000000000002190 | PMID 42326457 Get It

Acute hyponatremia is an uncommon complication of percutaneous cholecystostomy drainage with minimal literature to date. We present a case of a patient with necrotizing pancreatitis causing perforated cholecystitis, requiring percutaneous cholecystostomy that was complicated by acute hyponatremia. High biliary solute and volume loss led to the hyponatremia and elucidated downstream biliary obstruction. Fluid resuscitation, biliary stenting, and endoscopic drainage corrected the patient's sodium and symptoms in this multidisciplinary case.
Variation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Jones, Jennifer M. , Aldarweesh, Fatima , Aqui, Nicole, Bobr, Aleh , Brunker, Patricia A. R. , Covington, Mischa L. , Guarente, Juliana , Hagar, Robert, Karafin, Matthew, Lamba, Divjot Singh , Lee, Grace M. , Mack, Ethan A. , Muthur, Gagan, Nazli, Saadiya, Olaniyan, H S, Raval, Jay S., Setya, Divya , Tanhehco, Yvette C. , Thant, Mamie, Wu, Yanyun , Wong, Edward C.C. , Zheng, Yan , Brunker, Patricia A R , Lee, Grace , Lu, Wen , Mack, Ethan A , Onyenekwu, Chinelo P , Setya, Divya , Tanhehco, Yvette C , Vivero, Angelica , Yurtsever, Nalan , Zheng, Yan , Shi, Patricia A , Webb, Jennifer , Aldarweesh, Fatima , Aqui, Nicole A., Hagar, Robert Ward, Lu, Wen , Nazli, Saadiya , Yurtsever, Nalan , Shi, Patricia A.

Mayo Clinic

Journal of Clinical Apheresis | June 19, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70146 | PMID 42316838 Get It

ABSTRACT Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.
Elective genomic sequencing for adults in research, clinical and commercial contexts
Linderman, Michael D. , Adelson, Sophia , Berro, Tala , Crawford, Scott , Cunningham, Tshaka J., Esplin, Edward D. , Ewing-Crawford, Altovise T, Nielsen, Daiva E. , Andrighetti, Heather, Bleyl, Steven B., Haverfield, Eden , Hegde, Madhuri , Konstantinos, Lazaridis N, Leonard, Debra G. B. , May, Thomas , McGinniss, Molly, Pandya, Vaibhav, Schadt, Eric E. , Zettler, Bethany , Team, PeopleSeq Study, Adelson, Sophia M , Berro, Tala M , Crawford, Scott D , Esplin, Edward D , Nielsen, Daiva E , Pereira, Stacey , Schmidlen, Tara , Haverfield, Eden V , Hegde, Madhuri , Kruszka, Paul , Leonard, Debra , May, Thomas , Schadt, Eric E , Tzovaras, Bastian Greshake , Zettler, Bethany , McGuire, Amy L , Green, Robert C. , Berro, Tala M., Anderson, Jennifer L., Cunningham, Tshaka, Ewing, Altovise T. , Nielsen, Daiva E., Church, George M. , Konstantinos, Lazaridis N., McGinniss, Molly A. , Schadt, Eric E., Green, Robert C., Juusola, Jane , McWalter, Kirsty , Esplin, Ed, Haverfield, Eden, Hazell, Allison, Gu, Jessica, Hogan, Jennifer, Church, George , Ball, Mad Price , McGinnis, Molly, Schadt, Eric, Linderman, Michael, McGuire, Amy, Christensen, Kurt D. , Caskey, Thomas, Zoltick, Emilie S. , Crawford, Scott, Young, Robert, Hunsanger, Jillian, Bradley, Sophia, Cunningham, Tshaka, Roberts, Scott, Ricks‐Santi, Luisel , Lillard, James, Washington, Kareem N., Johnson, Anthony

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355296 | PMID 42369514 Get It

Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Isolated Axillary Lymphadenopathy in Women Without a Known Breast Cancer Diagnosis: A Multicenter Study of Biopsy Outcomes
Coffey, Kristen, Zamora, Kathryn, Miller, Trevor, Tavana, Anahita , Colvin, Stephanie, Thomas, Charlene , Coffey, Kristen , Maimone, Santo , Zamora, Kathryn , Miller, Trevor E., Dodelzon, Katerina

Mayo Clinic

American Journal of Roentgenology | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.2214/ajr.26.34937 | PMID 42308094 Get It

Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Survival Trends in Waldenström Macroglobulinemia and Comparison of Outcomes with the General US Population
Zanwar, Saurabh , Khan, Muhammad Azeem , Gaur, Gunjan , Abeykoon, Jithma P. , Gertz, Morie A. , Kumar, Shaji , King, Rebecca, Habermann, Thomas M. , Go, Ronald S. , Abdallah, Nadine , Thanarajasingam, Gita , Thompson, CM, Nowakowski, Grzegorz S. , Dasari, Surendra , Novak, Joseph, Warsame, R., Ansell, Stephen M. , Kapoor, Prashant , Go, Ronald S , Gertz, Morie A , Habermann, Thomas , Paludo, Jonas , Cook, Joselle , Buadi, Francis K. , Dispenzieri, Angela , Gonsalves, Wilson I. , Dingli, David , Muchtar, Eli , Greipp, Patricia T. , Novak, Joseph P. , Warsame, Rahma , Witzig, Thomas E. , Rajkumar, S. Vincent

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9904019/v1 Get It

Abstract Therapeutic options for Waldenström macroglobulinemia (WM) have expanded but improvements in overall-survival (OS) are difficult to interpret due to competing non–WM mortality. We conducted a large single-center retrospective study of 1,020 patients with WM to evaluate survival trends. Patients were stratified by era of active WM diagnosis using a two-era model (1996–2005 and post-2005) and a four-era model (pre-2001, 2001–2007, 2008–2013, and post-2013). OS did not differ significantly across eras in the overall cohort (p = 0.64 and p = 0.86 for the two- and four-era models). However, among patients aged < 65 years at the time of active WM diagnosis in the 2-era model, OS improved in the post-2006 era (median 18.8 vs 14.1 years, p = 0.018). Cause-specific-survival (CSS) improved across all eras, increasing from 15.6 years in 1996–2005 to 18.9 years post-2006 (p < 0.0001), and from 13.7 years pre-2001 to not reached in later periods in the four-era model (p < 0.0001). Competing-risk-analysis (CRA) demonstrated a reduction in WM-related mortality over time (p < 0.001). However, excess mortality persisted, with a standardized mortality ratio (SMR) of 2.79 (p < 0.001) among patients < 65 years compared with a matched U.S. population. Our findings highlight improvements in WM-specific survival, while gains in OS are observed in younger patients.
Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy
Roessler, Navid , Nowicka, Zuzanna , Miszczyk, Marcin , Calleris, Giorgio , Dematteis, Alessandro , Vetterlein, Malte W. , Albisinni, Simone , Poel, H J van der, Cathcart, Paul, Cacciamani, Giovanni , Persad, Raj , Joniau, Steven , Sanchez‐Salas, Rafael , Smith, Joseph A. , Karnes, R. Jeffrey , Ahmed, Mohamed E., Rajwa, Paweł , Shariat, S, Party, the Young Academic Urologists Prostate Cancer Working, Cacciamani, Giovanni E , Gill, Inderbir S , Persad, Raj A , Joniau, Steven , Sanchez-Salas, Rafael , Smith, Joseph A , Karnes, Jeffrey , Rajwa, Pawel , Tilki, Derya , Gontero, Paolo , Marra, Giancarlo , Miszczyk, Marcin , Cathcart, P. , Gill, Inderbir S. , Tilki, Derya , Shariat, Shahrokh F. , Gontero, Paolo , Marra, Giancarlo

Mayo Clinic

BJU International | June 16, 2026 | Volume: 138 | Issue: 3 | Pages: 430-437

10.1111/bju.70352 | PMID 42298374 Get It

Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non‐metastatic, hormone‐sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two‐stage approach: (i) at the individual‐patient level by fitting Clayton copula models and estimating Kendall's ( >0.7 indicating a strong association) and (ii) at the centre level, by fitting weighted linear regression of 5‐year OS on 3‐year BRFS and MFS. Results The two‐step analysis included 759 patients for BRFS (366 events) and 476 for MFS (137 events), with median follow‐up of 37 months (95% confidence interval [CI] 36–42 months) and 34 months (95% CI 31–37 months), respectively. At the individual‐patient level, MFS showed a strong association with OS (Kendall's 0.85, 95% CI 0.82–0.88), which was not observed for BRFS (Kendall's 0.63, 95% CI 0.56–0.69). At the centre level, neither 3‐year BRFS ( R 2 = 0.15; slope = 0.34, P = 0.2) nor 3‐year MFS ( R 2 = 0.21; slope = 0.26, P = 0.14) predicted 5‐year OS with sufficient explanatory power. Limitations include the fact that centre‐level analysis was based on single‐arm associations rather than on treatment‐effect surrogacy across arms, and retrospective data collection. Conclusions The BRFS should not be used as a surrogate endpoint in the sRP setting. MFS requires further validation in future prospective studies to confirm its association with OS. Patient‐reported outcomes, such as quality‐of‐life and treatment‐related toxicity, should be considered in parallel with OS.
International Delphi consensus on single‐port robotic radical prostatectomy: patient selection, surgical technique, and training
Soputro, Nicolas , Bjurlin, Marc, Srivastava, Abhishek , Umbreit, Eric, Eltemamy, Mohamed , Pak, Raymond, Gelikman, David G. , Hopson, Nicholas, Geskin, Albert , Mehrazin, Reza, VanDyke, Maia, Nguyen, Carvell, Ornstein, David, Billah, Mubashir , Russell, Christopher, Yuh, Bertram, Thong, Alan, Olivares, Ruben, Shetty, Sugandh, Shakuri‐Rad, Jaschar , Baccala, Angelo, Osinski, Thomas, Simone, Giuseppe, Lee, D Y , Baker, Mark, Ramadan, Mohammad, Mattei, Agostino , Jafri, Mohammad, Galfano, Antonio, Link, Richard E. , Lam, Po, Jones, Marklyn, Bassett, Jeffrey C. , Musi, Gennaro, Schwen, Zeyad , Beksaç, Alp Tuna , Eden, C, Miller, Scott, Gontero, P, Amparore, Daniele, Porpiglia, Francesco, Vourganti, Srinivas , Ahmed, Mutahar, Montorsi, Francesco, Perdona, Sisto, Izzo, Alessandro, Stifelman, Michael D., Crivellaro, Simone, Briganti, Alberto, Kaouk, Jihad, Autorino, Riccardo, Soputro, Nicolas A , Eltemamy, Mohamed , Gelikman, David G , Geskin, Albert , Palese, Michael , Link, Richard E , Rais‐Bahrami, Soroush , Bjurlin, Marc A. , Umbreit, Eric , Mehrazin, Reza , VanDyke, Maia , Yuh, Bertram, Thong, Alan Eih Chih , Olivares, Ruben , Baccala, Angelo A., Osinski, Thomas L. , Simone, Giuseppe , Crouzet, Sébastien , Ramadan, Mohammad Said , Porreca, Angelo , Jafri, Syed M., Galfano, Antonio , Amparore, Daniele , Ahmed, Mutahar, Montorsi, Francesco , Perdonà, Sisto , Izzo, Alessandro , STIFELMAN, MICHAEL D. , Crivellaro, Simone, Briganti, Alberto , Kaouk, Jihad , Autorino, Riccardo

Mayo Clinic

BJU International | June 16, 2026 | Volume: 138 | Issue: 3 | Pages: 456-463

10.1111/bju.70346 | PMID 42297464 Get It

Introduction The introduction of the purpose‐built single‐port (SP) robotic platform has allowed for the advent of regionalized minimally invasive surgical approaches for robotic radical prostatectomy (RARP), including the extraperitoneal and transvesical techniques. This study sought to develop a best practice consensus on the key principles, patient selection, surgical techniques, expected clinical outcomes, and learning curves pertaining to SP‐RARP. Methods A modified Delphi consensus was developed by a panel of experts, consisting of a 33‐item questionnaire, with each statement rated using a binary Likert scale (‘agree’ or ‘disagree’). The survey was distributed via email to all practicing SP‐RARP surgeons across the USA and Europe. Consensus was defined as ≥75% agreement on a given statement. Results A total of 53 surgeons participated in the Delphi Consensus across the two rounds. Of 33 statements, 28 (84.8%) reached agreement in the first round. The remaining consensus was achieved in the second round, involving 35 surgeons, and with one additional statement. The panel agreed that, although are no absolute contraindications to SP‐RARP, the preference towards specific SP‐RARP techniques should remain guided by the individual patients and surgical expertise. Although the SP extraperitoneal technique is recommended to pursue pelvic lymph node dissections, the panel agreed that transvesical SP‐RARP showed promise in promoting shorter hospital stay, faster recovery of urinary continence, and utility in patients with extensive prior abdominal surgery. Consensus was also reached on the need for a structured training pathway, with most recommending beginning with extraperitoneal SP‐RARP before advancing to the transvesical approach. Conclusion This Delphi consensus demonstrates broad agreement among experienced SP surgeons in the USA and Europe, forming the foundation for future research on the clinical utility and necessary training pathways for SP‐RARP. Nevertheless, empirical validation based on clinical data from large cohort studies remains important.
An Annual Review of Important Apheresis Articles in 2025 From the American Society for Apheresis Attending Physician Subcommittee
Zantek, Nicole D. , Lu, Wen , AlMozain, Nour , Lu, Wen , Almozain, Nour , Alsammak, Mohamed , Gupta, Gaurav K , Levenbrown, Yosef , Li, Yanhua , Tripathi, Parmatma Prasad , Tanhehco, Yvette C , Zantek, Nicole D , Dilly, Laura, Martin, Marisa C. Saint, Alsammak, Mohamed , Banez‐Sese, Grace, Chhibber, Vishesh, Costa, Victoria, DeChristopher, Phillip J., Durlen, Ivan , Gupta, Gaurav K. , Li, Yanhua , Mattiazzi, Adela D. , Noland, Daniel K., Prajapati, Vipulkumar, Singh, Nirupama, Siwach, Garima, Wu, Ding Wen , Wehrli, Gay , Tanhehco, Yvette C.

Mayo Clinic

Journal of Clinical Apheresis | June 13, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70142 | PMID 42287024 Get It

ABSTRACT Apheresis medicine is a continually evolving field with numerous studies published each year. To help apheresis practitioners stay up to date with the current literature, members of the American Society for Apheresis (ASFA) Attending Physician Subcommittee identified and summarized 10 seminal articles published in 2025, from the field of apheresis medicine. PubMed was used to identify articles published in four topics including donor apheresis, therapeutic apheresis, apheresis education, and apheresis collection for cellular therapy. These articles met at least one of the following criteria: novel findings, practice‐altering outcomes, international in scope, randomized‐controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA 9th Special Issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach. Full length, peer‐reviewed manuscripts in English with data from human subjects were included while case reports, review articles, and meta‐analyses were excluded.
Pediatric epilepsy surgery: Global survey of invasive explorations
Ramantani, Georgia , Feucht, Martha , Cserpán, Dorottya , Aparicio, Javier , Arzimanoglou, Alexis , Bartoloméi, Fabrice , Bingaman, William , Braun, Kees P. J. , Burman, Richard J. , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cross, J. Helen , Cukiert, Cristine Mella , Curry, Daniel J. , Dimova, Petia , Eltze, Christin , Hallböök, T , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt, Patil, Sandeep Bhagwan , Pérez‐Jiménez, María Ángeles, Pérez‐Poveda, Juan Carlos , Pieper, Tom , Rona, Sabine, Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta‐Arsene, Oana , Tripathi, Manjari , Moosa, Ahsan N. , Weiner, Howard , Cai, Lixin , Sorbets, Sarah Ferrand , Group, ILAE Pediatric Epilepsy Surgery Taskforce and Study, Barba, Carmen , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cross, Helen J , Cukiert, Arthur , Curry, Daniel J , De Palma, Luca , Dimova, Petia , Eltze, Christin , Englot, Dario J , Nico Enslin, Johannes M , Fallah, Aria , Francione, Stefano , Gill, Deepak , Harvey, A Simon , Holthausen, Hans , Jayalakshmi, Sita , Jiang, Yuwu , Kannan, Lakshminarayanan , Lallas, Matt , Patil, Sandeep Bhagwan , Pérez-Poveda, Juan Carlos , San Antonio-Arce, Victoria , Shetty, Jay , Smith, Mary Lou , Suwanpakdee, Piradee , Tarta Arsene, Oana , Tassi, Laura , Tisdall, Martin M , Tripathi, Manjari , Valappil, Ahsan Moosa Naduvil , Wirrell, Elaine C , Cai, Li-Xin , Ferrand Sorbets, Sarah , Wilmshurst, Jo M , Ramantani, Georgia , Feucht, Martha , Burman, Richard J , Englot, Dario J. , Enslin, Nico , Fallah, Aria , Gill, Deepak , Pérez-Jiménez, María Ángeles, Tisdall, Martin , Wirrell, Elaine , Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Barba, Carmen

Mayo Clinic

Epilepsia | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70325 | PMID 42274288 Get It

Abstract Objective Invasive presurgical evaluation plays a key role in pediatric epilepsy surgery, particularly in magnetic resonance imaging (MRI)‐negative cases, by guiding resective, disconnective, or ablative procedures. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Taskforce study provides an updated global overview of current invasive evaluation practices. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) in 29 countries across six continents. Included were children and adolescents who underwent presurgical evaluation and epilepsy surgery in 2023. The study was designed to enable comparison with the similar ILAE survey conducted in 2004. Results A total of 2427 patients were included. Invasive evaluations were performed in 21.1% of cases, most frequently in North America (33.7%, higher than Europe: 18.0%, p = .003). Among invasive cases, 32.3% had no detectable MRI abnormalities. The main indication for invasive evaluation was seizure onset localization (88.1%), followed by motor or sensory mapping (17.2%) and language mapping (14.2%). Stereoelectroencephalography (SEEG) was the predominant technique (19.8% overall, 93.6% of invasive cases), more common in North America (30.0%, p = .021) and less common in South America (7.4%, p < .001). Subdural electrodes were used in only 3.2% of invasive cases, and combined depth and subdural approaches in 3.2%. SEEG‐guided radiofrequency thermocoagulation (RF‐TC) was performed in 40.9% of SEEG cases, most commonly in Asia (63.8%). In 16.2% of invasive evaluations, patients did not proceed to resection, disconnection, or ablation, with the highest rate in Europe (28.5%). Significance This global survey provides the first broad overview of invasive evaluation practices in pediatric epilepsy surgery across participating centers worldwide. It highlights the widespread adoption of SEEG, declining use of subdural electrodes, and increasing application of SEEG‐guided RF‐TC. The high proportion of MRI‐negative cases and the considerable proportion of patients not proceeding to resection, disconnection, or ablation underscore the complexity of contemporary surgical candidates and the need for further refinement of selection strategies.